COMMUNIQUÉS West-GlobeNewswire

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
27/03/2026
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
27/03/2026
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and [...]
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
27/03/2026
sNDA submitted seeking approval of IGALMI ® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential [...]
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
27/03/2026
Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with [...]
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
27/03/2026
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Arletta Pharma Solutions Announces Positive Results from Phase II Clitoral Doppler Duplex Ultrasound Study of Lybrido™ Combination Targeting Female Sexual Dysfunction
27/03/2026
www.arlettapharmasolutions.com More than 60% average improvement in clitoral blood flow observed with both dose-combinations Statistical significance achieved with new high dose-combination despite small sample size [...]
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
27/03/2026
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs , Inc. (Nasdaq: AIDX), an early market [...]
Notification of managers’ transactions
27/03/2026
ANNOUNCEMENT NO. 305 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Articles of Association for Novo Nordisk A/S 2026
27/03/2026
Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
27/03/2026
MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge 1 , a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security- [...]
Zelluna ASA – Mandatory notification of trade
27/03/2026
Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA ( Zelluna ), has today entered into an agreement with Radforsk Investeringsstiftelse ( [...]
Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers
27/03/2026
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma 1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to [...]
Notification of managers’ transactions
27/03/2026
ANNOUNCEMENT NO. 306 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
27/03/2026
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) , a rare primary immunodeficiency Decision based on [...]
IBA réalise des résultats solides pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments
27/03/2026
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats annuels 2025 Louvain-La-Neuve, Belgique, 27 mars 2026 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour l' [...]
UCB - Convocation à l'assemblée générale des actionnaires 2026
27/03/2026
CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration invite les actionnaires à l’assemblée générale des actionnaires (« l’Assemblée Générale ») qui se tiendra le jeudi 30 avril 2026 à 11 [...]
IBA delivers strong FY 2025 results with solid execution in all segments
27/03/2026
Read the entire full-year 2025 results press release here Louvain-la-Neuve, Belgium, 27 March 2026 - IBA (Ion Beam Applications S.A.), today announces its consolidated results of 2025 financial year, with strong [...]
Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
27/03/2026
Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27 [...]
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
27/03/2026
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate [...]

Pages